Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab + mezigdomide + dexamethasone in relapsed/refractory multiple myeloma
2026-526352-31-00Phase 2Authorised
- Sponsor
- PETHEMA
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elranatamab, mezigdomide and dexamethasone in multiple myeloma (MM), sponsored by PETHEMA. Primary endpoint: MRD negativity rate. Planned start Oct 2026; status: authorised.
02
Drugs
elranatamabmezigdomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2026-526352-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526352-31-00.